D uring cancer progression, many cancer cells delete tumour-suppressor genes that block tumour development. This deletion process often also removes some neighbouring genes. The partial or complete loss of these neighbouring genes can make cancer cells vulnerable to therapeutic targeting -a concept known as collateral lethality 1 . On page 119, Dey et al. 2 reveal an example of collateral lethality in pancreatic cancer that exploits changes in cellular metabolism.
Collateral lethality is based on the premise that cancer cells survive co-deletion of neighbouring genes that have essential functions because such a loss is functionally compensated for by a closely related gene elsewhere in the genome. Targeting these closely related genes should be lethal only to tumour cells that have lost the initial genes, offering a cancerselective therapeutic strategy. A similar concept has been exploited clinically for tumours with a deficiency in BRCA genes, which have a role in a DNA-repair pathway 3 . These BRCA-deficient tumours have an impaired DNA-repair capacity and are vulnerable to the inhibition of an alternative DNA-repair pathway that is dependent on PARP proteins 4 . There have been promising clinical results for use of PARP inhibitors as a component of therapy for breast and ovarian cancer 4 . Pancreatic ductal adenocarcinoma is an aggressive malignancy that has a dismal clinical prognosis. There is, therefore, an urgent need for improved treatments. Despite considerable advances in our understanding of pancreatic cancer biology, there is no lasting effective clinical therapy for late-stage pancreatic ductal adenocarcinoma, and current treatments provide an increase in survival of just a few months 5, 6 . Altered cellular metabolism is a characteristic of tumour cells, which creates an opportunity to develop new classes of anticancer agent 7 . Pancreatic cancer cells harbour extensively rewired metabolic networks because of the activity of the KRAS protein 8 . This has implications for drug development because molecules downstream of the KRAS pathway are potential cancer-specific targets for therapeutic intervention.
In addition to the high frequency of mutations of the KRAS gene that generate a tumour-promoting KRAS protein, pancreatic ductal adenocarcinoma is characterized 9 by in activation of some tumour-suppressor genes, including SMAD4. Dey et al. focused on the subset of pancreatic ductal adenocarcinoma cells that harbours a deletion of both copies of the SMAD4 gene, and they found that this subset is associated with the loss of neighbouring genes involved in essential metabolic pathways. One of these neighbouring genes is mitochondrial malic enzyme 2 (ME2). The authors noted that a decrease in ME2 expression leads to compensatory increased expression of the closely related protein mitochondrial malic enzyme 3 (ME3). The low expression of ME3 observed in normal cells makes the protein an appealing target for a cancer-specific therapeutic approach, because depletion of its function would affect only cancer cells that express ME3 at high levels
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Double trouble for tumours
When some cancer cells delete a tumour-suppressor gene, they also delete nearby genes. It emerges that one of these latter genes has a key metabolic role, revealing a therapeutic opportunity that might be relevant for many tumours. See Letter p.119 In normal cells, the tumour-suppressor gene SMAD4 neighbours the ME2 gene, which encodes an enzyme that has an essential role in cellular metabolism. Dey et al. 2 observed that deletion of SMAD4 in human pancreatic ductal adenocarcinoma can be associated with the loss of ME2. This loss leads to an increase in expression of the closely related enzyme ME3, which can provide functional compensation for the essential metabolic functions carried out by ME2. Normal cells usually express low levels of ME3 and do not die if it is deleted. However, if ME3 is deleted in cancer cells that lack ME2, this causes cell death because of metabolic abnormalities that include low levels of the cofactor NADPH and of the amino acid glutamate, and high levels of reactive oxygen species (ROS). This approach of investigating metabolic vulnerabilities and the role of genes co-deleted with tumour-suppressor genes offers a new framework for finding therapeutic targets.
and leave the normal cells unaffected.
ME2 and ME3 function in the conversion of the metabolic molecule malate to pyruvate, which is a key molecule in several metabolic pathways. These enzymes are also involved in the regeneration of the cofactor NADPH, which is needed for the metabolic processes that produce the nucleotide ATP, the cell's main energy-carrying molecule 10 . The authors demonstrated that, on loss of ME2, the resulting compensatory increase in ME3 is sufficient to maintain the metabolic processes that lead to ATP production and support the high energetic and biosynthetic demands of proliferating cancer cells. Furthermore, the authors demonstrated that ME2 deletion makes cells vulnerable to ME3 loss in human pancreatic-cancer cell lines and mouse transplantation models of pancreatic cancer. They found that this sensitivity is due to several metabolic impairments of cancer cells that lack ME2, including deficiency in the function of mitochondrial organelles; low levels of NADPH; high levels of reactive oxygen species, which act in redox pathways; and impaired regeneration of the amino acid glutamate, an indispensable metabolite for pancreatic cancer cells. The authors found that deletion of both ME2 and ME3 thus results in cancer-cell death and impaired tumour maintenance (Fig. 1) .
These findings reveal a previously unknown vulnerability of pancreatic ductal adenocarcinoma because of the cells' altered metabolism, and highlight the potential for drug targeting of the rewired metabolic pathways of cancer cells. Targeting of the altered redox state of pancreatic cancer has emerged 11 as a promising therapeutic approach. In KRAS-driven cancer cells, the effect of excessive cellular oxidation produced by increased mitochondrial activity needs to be counteracted by high production of anti oxidant molecules 12 . Impairing antioxidant function might drive cancer-cell oxidation to toxic levels, revealing additional possibilities for clinical approaches and providing justification for KRAS-driven cancer therapies designed to include oxidizing agents or other agents that target redox dependencies.
However, targeting metabolic and redox vulnerabilities of cancer cells could ultimately drive the development of treatment resistance. Therefore, improvements in our understanding of metabolic and redox networks will probably be needed to tackle the evasion of such selective therapies. Nevertheless, targeting the key molecules required to enable metabolic and redox rewiring in cancer cells is a promising therapeutic strategy. Although drugs targeting genes that promote cancer development (oncogenes) will doubtless continue to be a source of treatments, pursuing collateral lethality targets as an associated approach might also reveal therapeutic opportunities.
Dey et al. investigated a situation in which both copies of a metabolic gene that neighbours a tumour-suppressor gene were lost. However, the loss of one copy of other essential genes might also generate collateral dependencies. This single-copy loss might be specific to individual tumours or could be more widely relevant if linked to frequently lost tumoursuppressor genes. Such a view of cancer might expand horizons of potential therapeutic targets and enable the delivery of truly personal ized medical care. ■ 
Giulia Biffi
T he physical and chemical properties of binary alloys -metals that consist of two elements -can be tuned by varying the composition and arrangement of their atoms. Alloys made of iron (Fe) and platinum (Pt) are of particular interest because they can yield one of the magnetically 'hardest' materials (magnetization is retained for a long time) as well as one of the magnetically softest. On page 75, Yang et al. 1 report a quantitative experimental study of a binary alloy at the single-atom level. Using an 8.4-nanometre FePt nanoparticle, the authors demonstrate a state-of-the-art approach for determining the 3D atomic arrangement of such particles. Their technique could also lead to a better understanding of how nanoparticles form from initially small clusters of atoms.
At the nanoscale, every atom counts. For example, changing the relative positions of a few Fe and Pt atoms in a FePt nanoparticle dramatically alters the particle's properties, such as its response to a magnetic field. Why is this? For a particle that has a diameter smaller than 9 nm, 8% or more of its atoms reside on the surface 2 . Pt is a very good catalyst, so moving some of these atoms to the surface increases the particle's catalytic activity 3 . At the same time, this would strengthen such a particle's magnetism because Fe atoms would have been pushed to the centre. Bifunctional (hybrid) nanoparticles can therefore be obtained in which catalytic and magnetic properties can be tuned by repositioning the respective elements.
Yang and colleagues used an imaging technique called atomic electron tomography to determine the shape of an 8.4-nm FePt particle and the 3D positions of its 23,196 atoms. First, the authors passed an electron beam through the nanoparticle at a fixed angle and used the scattering of the beam to produce a 2D image, or projection, of a slice of the particle (Fig. 1a) . They then rotated the particle through angles of −65.6° to +64.0° and recorded a series of 68 such projections. Finally, Yang et al. used impressive numerical simulations to combine the 2D images, producing a 3D reconstruction of the particle, in which the individual Fe and Pt atoms are clearly distinguishable.
The authors achieved a remarkable spatial resolution of 22 picometres (1 pm is 10 −12 m), corresponding to roughly one-tenth of the diameter of the atoms -this allowed the position of each atom to be determined. This resolution, however, is insufficient for analysing small changes in atomic positions owing to strain or surface-relaxation effects 4 . Nevertheless, the authors' experimental data provide us with a much better understanding of how small clusters of atoms combine to form nanoparticles.
Yang et al. also looked at the magnetic properties of their FePt nanoparticle. The fraction of atoms that exist on the surface of such particles is large. These surface atoms have a smaller number of nearest neighbours than
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Nanoparticle atoms pinpointed
The locations of atoms in a metallic alloy nanoparticle have been determined using a combination of electron microscopy and image simulation, revealing links between the particle's structure and magnetic properties. See Letter p.75
